Why ANI Pharmaceuticals Inc. Stock Roared Higher

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ANI Pharmaceuticals , a specialty developer of branded and generic drugs, roared higher by as much as 11% after the company announced the acquisition of the drug Lithobid from Noven Therapeutics.

So what: According to ANI Pharmaceuticals' midday press release, total consideration paid for the extended release tablets, which treat manic episodes of bipolar disorder, was $12 million. This includes an $11 million up-front payment from ANI to Noven, as well as $1 million in future sales milestone payments. ANI anticipates launching Lithobid this month under its own label, with the purchase expected to annually add $4 million in revenue and $3.9 million in adjusted EBITDA. As ANI's president and CEO pointed out, "Prior to the acquisition, ANI contract manufactured Lithobid, which allows us to immediately launch ANI-labeled product."

Now what: ANI said the magic words in its press release: "immediately accretive" to earnings. ANI has largely developed its generic portfolio through internal discoveries, but it made waves recently with two mature drug purchases, including today's buy. In December, it acquired 31 generic drugs from Teva Pharmaceutical for $12.5 million and a percentage of gross profits from future product sales. ANI's ability to supplement its high-margin branded portfolio with both internal and external generic drugs makes me believe that it has the potential to head even higher over the long term.

ANI may have soared today, but the enormous potential from this revolutionary product could leave ANI in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The article Why ANI Pharmaceuticals Inc. Stock Roared Higher originally appeared on Fool.com.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading